GlassScriptPhysician profile
Robert D Hong
NPI 1023072477
$4,678.91
in general payments reported to CMS, 2019-2025
39 companies · $590 in 2025
The $590 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $205 · 2021: $712 · 2022: $865 · 2023: $1,068 · 2024: $602 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,258 · Education: $2.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,257.60 |
| Education | $2.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $503.53 | 2019-2025 | |
| Janssen Biotech, INC. | $497.10 | 2019-2025 | Erleada, Akeega, Balversa |
| Astrazeneca Pharmaceuticals LP | $479.77 | 2020-2025 | Lynparza |
| Astellas Pharma US INC | $413.87 | 2019-2024 | Myrbetriq, Xtandi, Veozah |
| Abbvie INC. | $350.16 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $338.46 | 2023-2025 | Orgovyx, Gemtesa |
| Merck Sharp & Dohme LLC | $256.38 | 2020-2025 | Keytruda, Lynparza |
| Urogen Pharma, INC. | $213.39 | 2021-2024 | Jelmyto |
| Dendreon Pharmaceuticals LLC | $196.48 | 2020-2023 | Provenge |
| Immunitybio, INC. | $175.66 | 2025 | |
| Boston Scientific Corporation | $123.96 | 2019-2022 | |
| Teleflex LLC | $122.59 | 2024-2025 | Urolift, Barrigel |
| Bayer Healthcare Pharmaceuticals INC. | $111.26 | 2019-2024 | |
| Urovant Sciences INC | $96.57 | 2021-2022 | |
| Amgen INC. | $94.39 | 2019-2021 |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$986.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.